## Supplemental Table 1

	Comparison	Significance	Adjusted P Value	
Total	N4 vs. Y3	****	< 0.0001	
	N4 vs. T4	****	< 0.0001	
	N4 vs. N4 1000	ns	0.1714	
	Y3 vs. T4	ns	0.9088	
	Y3 vs. N4 1000	*	0.0123	
	T4 vs. N4 1000	***	0.0003	
iv+	N4 vs. Y3	****	< 0.0001	
	N4 vs. T4	****	< 0.0001	
	N4 vs. N4 1000	ns	0.2434	
	Y3 vs. T4	ns	0.9476	
	Y3 vs. N4 1000	*	0.0484	
	T4 vs. N4 1000	**	0.0031	
-vi	N4 vs. Y3	****	< 0.0001	
	N4 vs. T4	****	< 0.0001	
	N4 vs. N4 1000	*	0.0391	
	Y3 vs. T4	ns	0.9343	
	Y3 vs. N4 1000	*	0.0294	
	T4 vs. N4 1000	***	0.0006	
	iv- iv+ Total	Comparison   N4 vs. Y3   N4 vs. T4   N4 vs. T4   N4 vs. N4 1000   Y3 vs. T4   Y3 vs. N4 1000   T4 vs. N4 1000   T4 vs. N4 1000   T4 vs. N4 1000   Y3 vs. T4   Y3 vs. N4 1000   Y3 vs. T4   Y3 vs. T4   Y3 vs. N4 1000   Y3 vs. N4 1000   T4 vs. N4 1000   Y3 vs. T4   Y3 vs. T4   Y3 vs. N4 1000   T4 vs. N4 1000   Y3 vs. T4   Y3 vs. N4 1000   Y3 vs. N4 1000   T4 vs. N4 1000   T4 vs. N4 1000   T4 vs. N4 1000	Comparison Significance   N4 vs. Y3 ****   N4 vs. T4 ****   N4 vs. T4 ****   N4 vs. T4 ****   N4 vs. N4 1000 ns   Y3 vs. T4 ns   Y3 vs. N4 1000 *   T4 vs. N4 1000 ****   N4 vs. Y3 ****   N4 vs. T4 ns   Y3 vs. T4 ns   Y3 vs. N4 1000 *   .4 vs. N4 1000 **   N4 vs. T4 *****   N4 vs. Y3 *****   .4 vs. N4 1000 *   Y3 vs. T4 ns   Y3 vs. N4 1000 *   Y3 vs. N4 1000 *   Y3 vs. N4 1000 *   Y3 vs. N4 1000 ****	

		Comparison	Significance	Adjusted P Value	
<b>B</b> 10 dpi lung OT-I	Total	N4 vs. Y3	***	0.0007	
		N4 vs. T4	****	< 0.0001	
		N4 vs. N4 1000	****	< 0.0001	
		Y3 vs. T4	ns	0.1619	
		Y3 vs. N4 1000	ns	0.8948	
		T4 vs. N4 1000	ns	0.5397	
	+vi	N4 vs. Y3	****	< 0.0001	
		N4 vs. T4	****	< 0.0001	
		N4 vs. N4 1000	ns	0.1837	
		Y3 vs. T4	ns	0.8098	
		Y3 vs. N4 1000	ns	0.0928	
		T4 vs. N4 1000	**	0.0029	
		N4 vs. Y3	***	0.001	
		N4 vs. T4	****	< 0.0001	
	iv-	N4 vs. N4 1000	****	< 0.0001	
		Y3 vs. T4	ns	0.1376	
		Y3 vs. N4 1000	ns	0.7232	
		T4 vs. N4 1000	ns	0.7391	

C 34 dpi spleen OT-I	Total	N4 vs. Y3	*	0.0406			Total	N4 vs. Y3	ns	0.8253
		N4 vs. T4	***	0.0002				N4 vs. T4	****	< 0.0001
		N4 vs. N4 1000	*	0.046				N4 vs. N4 1000	*	0.0214
		Y3 vs. T4	ns	0.9168				Y3 vs. T4	*	0.0173
		Y3 vs. N4 1000	ns	> 0.9999				Y3 vs. N4 1000	ns	0.28
		T4 vs. N4 1000	ns	0.9453				T4 vs. N4 1000	ns	0.861
		N4 vs. Y3	ns	0.2058			iv+	N4 vs. Y3	ns	0.1399
		N4 vs. T4	**	0.0034		OT-I		N4 vs. T4	****	< 0.0001
	+	N4 vs. N4 1000	ns	0.177		bun		N4 vs. N4 1000	**	0.0045
	<u>&gt;</u>	Y3 vs. T4	ns	0.8822		dpi l		Y3 vs. T4	*	0.0482
		Y3 vs. N4 1000	ns	0.999		34		Y3 vs. N4 1000	ns	0.6265
		T4 vs. N4 1000	ns	0.9482				T4 vs. N4 1000	ns	0.6788
	iv-	N4 vs. Y3	*	0.0103			-vi	N4 vs. Y3	ns	0.9171
		N4 vs. T4	****	< 0.0001				N4 vs. T4	****	< 0.0001
		N4 vs. N4 1000	*	0.0153				N4 vs. N4 1000	*	0.0423
		Y3 vs. T4	ns	0.9501				Y3 vs. T4	*	0.0293
		Y3 vs. N4 1000	ns	> 0.9999				Y3 vs. N4 1000	ns	0.3029
		T4 vs. N4 1000	ns	0.9545				T4 vs. N4 1000	ns	0.9142

S. Table 1: One-way ANOVA statistical analysis of data sets from Fig. 1 A-D.



S. Figure 1 Endogenous virus-specific CD8<sup>+</sup> T cells are equivalently stimulated by influenza A viruses expressing high and low affinity OT-I epitopes. (A-F) CD45.1<sup>+</sup> OT-I T cells were transferred into CD45.2<sup>+</sup> hosts and were infected with 40 PFUs of IAV\_N4 or IAV\_T4. On indicated dpi, spleen and lungs were harvested after anti-CD8 $\alpha$  iv injections. (A and C) Representative flow plots of total host CD8<sup>+</sup> T cells for H-2D<sup>b</sup>-PA<sub>224</sub>/NP<sub>366</sub> tetramers and CD44, on 10 (A) or 34 (C) dpi. Numbers represent the percentage of cells in the gate. (B and D) The number of endogenous CD8<sup>+</sup> H-2D<sup>b</sup>-PA<sub>224</sub>/NP<sub>366</sub> tetramer<sup>+</sup> CD44<sup>hi</sup> cells, either total (iv<sup>+</sup> and iv<sup>-</sup> combined), iv<sup>+</sup>, or iv<sup>-</sup> cells at 10 (B) or 34 (D) dpi. (E) The number of iv<sup>-</sup> tetramer<sup>+</sup> CD8<sup>+</sup> T cells in the lung at 34 dpi was divided by the average number of total tetramer<sup>+</sup> CD8<sup>+</sup> T cells in the lung at 10 dpi. (F) The number of iv<sup>-</sup> tetramer<sup>+</sup> CD8<sup>+</sup> T cells in the lung at 10 dpi. (F) The number of iv<sup>-</sup> tetramer<sup>+</sup> CD8<sup>+</sup> T cells in the lung at 10 dpi. (F) The number of iv<sup>-</sup> tetramer<sup>+</sup> CD8<sup>+</sup> T cells in the lung at 10 dpi. (G) CD45.2<sup>+</sup> mice were infected with 40 PFUs of IAV\_N4 or IAV\_T4. Lungs were harvested at indicated dpi and virus titered by plaque assay. Dotted line represents the limit of detection. The results (B and D) are compiled from at least 5 independent experiments with at least 4 mice per group, per experiment (± SEM). The results (G) are from 1 experiment with 3 mice per group (± SEM). \*p < 0.05, \*\* p < 0.01, \*\*\*\*

**Supplemental Figure 2** 

0

IAV\_N4

IAV\_T4





**S. Figure 3 TCR affinity does not impact the production of effector molecules.** Challenged mice were generated as in Figure 1. On indicated dpi, lungs and spleens were harvested and cells were stimulated *ex vivo* with 1 µg/mL N4 peptide. (**A**,**E**) Representative granzyme B staining of iv<sup>-</sup> lung (**A**) or total spleen (**E**) OT-I T cells and CD44<sup>lo</sup> host cells stimulated with N4 peptide. (**C**) Representative IFN- $\gamma^+$  staining of total spleen OT-I T cells unstimulated, stimulated with PMA/Ionomycin or N4 peptide. (**B**) Percentage of iv<sup>-</sup> lung granzyme B<sup>+</sup> OT-I T cells after *ex vivo* N4 stimulation at 34 dpi. (**D**, **F**) Percentage of total spleen IFN- $\gamma^+$  (**D**) or granzyme B<sup>+</sup> (**F**) OT-I T cells after *ex vivo* N4 stimulation at 10 dpi. (**G**) Percentage of lung IFN- $\gamma^+$  OT-I T cells after *ex vivo* stimulation with 1 or 0.1 µg/mL of N4 or T4 peptides at 34 dpi. The results (**B**) are compiled from 2 independent experiments with at least 4 mice per group, per experiment (± SEM). The results (**D**, **F**, **G**) are from 1 experiment with at least 3 mice per group (± SEM). \*p < 0.05 (unpaired t test).